Dahlstrand Hanna, Näsman Anders, Romanitan Mircea, Lindquist David, Ramqvist Torbjörn, Dalianis Tina
Department of Oncology-Pathology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
Anticancer Res. 2008 Mar-Apr;28(2B):1133-8.
The aim of this review is to present the current knowledge on the status and significance of human papillomavirus (HPV) in tonsillar cancer. An increase in the incidence of tonsillar cancer has been reported and recent data suggest that this increase is due to an increased proportion of HPV in these tumours. Furthermore, patients with HPV positive cancer have been shown to have a lower risk of relapse and longer survival compared to patients with HPV-negative tonsillar cancer. Tailoring individual treatment in tonsillar cancer may be of importance in order to reduce patient suffering as well as to increase patient survival. Finally, the fact that the presence of HPV-type 16 E6 and E7 mRNA has been ascertained in tonsillar cancer suggests that HPV-16 indeed is an aetiological factor associated with the disease and that preventive vaccination for this patient group should be discussed.
本综述的目的是介绍目前关于人乳头瘤病毒（HPV）在扁桃体癌中的现状和意义的知识。据报道扁桃体癌的发病率有所上升，最近的数据表明这种上升是由于这些肿瘤中HPV比例增加所致。此外，与HPV阴性扁桃体癌患者相比，HPV阳性癌症患者的复发风险较低，生存期较长。为减少患者痛苦并提高患者生存率，在扁桃体癌中进行个体化治疗可能很重要。最后，已在扁桃体癌中确定存在HPV 16型E6和E7 mRNA这一事实表明，HPV 16确实是与该疾病相关的病因因素，应该讨论针对该患者群体的预防性疫苗接种。
